MedeliX
Start asking

Ergocalciferol

D.forte Ampul · ATC code A11CC01

Also known as: Ergokalsiferol

Key facts
Active substance
Ergocalciferol
Drug class
Vitamin D receptor modulator
ATC code
A11CC01
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-10-29

Key facts

Ergocalciferol (vitamin D₂) is used, per the US prescribing information, to treat hypoparathyroidism, vitamin D resistant rickets and familial hypophosphatemia.

What it is used for

  • Hypoparathyroidism.
  • Refractory rickets (vitamin D resistant rickets).
  • Familial hypophosphatemia.

Dosing

  • The range between therapeutic and toxic doses is narrow; dosage must be individualized under close medical supervision.
  • Vitamin D resistant rickets: 12,000 to 500,000 IU daily.
  • Hypoparathyroidism: 50,000 to 200,000 IU daily together with calcium lactate 4 g six times per day.
  • Check blood calcium and phosphorus every 2 weeks or more often if needed; bone X-rays every month until the condition is corrected and stabilized.
  • Vitamin D from fortified foods and supplements should be taken into account; readjust the dose as soon as there is clinical improvement.

Contraindications

  • Hypercalcemia, malabsorption syndrome.
  • Abnormal sensitivity to the toxic effects of vitamin D, hypervitaminosis D.

Important warnings

  • In vitamin D resistant rickets the therapeutic range is especially narrow; great care is needed to prevent serious toxic effects.
  • In hyperphosphatemia (e.g. renal osteodystrophy), maintaining normal serum phosphorus is essential to prevent metastatic calcification.
  • Adequate dietary calcium is necessary for a clinical response.
  • Contains tartrazine (FD&C Yellow No. 5), which may cause allergic-type reactions including bronchial asthma in susceptible people.
  • Effects can persist for two or more months after stopping treatment.

Side effects

  • Adverse effects are those of hypervitaminosis D with hypercalcemia: anorexia, nausea, weakness, weight loss, vague aches and stiffness, constipation, anemia, mild acidosis.
  • Impaired renal function with polyuria, nocturia, polydipsia, hypercalciuria, nephrocalcinosis and vascular calcification, up to irreversible renal insufficiency which may result in death.
  • Soft-tissue calcification (heart, blood vessels, renal tubules, lungs); in children, slowed linear growth.

Interactions

  • Mineral oil interferes with absorption of fat-soluble vitamins, including vitamin D.
  • Thiazide diuretics may cause hypercalcemia in hypoparathyroid patients.

Pregnancy and breastfeeding

  • Vitamin D in excess of the recommended dietary allowance should be avoided in normal pregnancy; safety above 400 IU daily has not been established.
  • Caution in nursing women: large maternal doses caused hypercalcemia in a child.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Turkey

  • D.forte AmpulGÜNSA GÜNEY İLAÇ VE HAMMADDELER SAN. VE TİC. A.Ş. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

USA

  • Vitamin DAvPAK · 9 register entries

Source: U.S. FDA – Drug labels (openFDA/DailyMed), as of 2026-10-29

Brand names in 3 more European countries
Czechia
Calciferol Bbp
France
Sterogyl
Slovakia
Calciferol Bbp

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. ERGOCALCIFEROL (Torrent Pharmaceuticals Limited) – Prescribing Information, 2026-09-04. DailyMed (NLM), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4ae38744-020d-4c37-a6f1-88f55c2f1047
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  3. U.S. FDA – Drug labels (openFDA/DailyMed), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/
  4. Wikidata (CC0): ATC A11CC.

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.